# Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
Canonical URL: https://biopharmsignal.com/news/HUMA/humacyte-announces-israeli-ministry-of-health-acceptance-of-marketing-authorization-application-for-symvessr-for-vascular-trauma-repair
Ticker: HUMA
Company: Humacyte
Source: Humacyte
Published: 2026-04-21 12:00 EST
Original Source URL: https://investors.humacyte.com
## Summary

- The Ministry of Health has set a 180-working-day review period for the MAA -  - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology

## Article Body
- The Ministry of Health has set a 180-working-day review period for the MAA -  - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology
## Recent Company News
- 2026-05-26 12:00 EST — [Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access](https://biopharmsignal.com/news/HUMA/humacyte-announces-presentation-at-vasa-meeting-of-research-highlighting-self-repair-of-atev-after-cannulation-for-dialysis-access) — Source: Humacyte
- 2026-05-20 12:00 EST — [Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs](https://biopharmsignal.com/news/HUMA/humacyte-announces-symvessr-is-now-under-contract-with-the-strategic-acquisition-center-sac-of-the-u-s-department-of-veterans-affairs) — Source: Humacyte
- 2026-05-13 11:00 EST — [Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/HUMA/humacyte-announces-first-quarter-2026-financial-results-and-provides-business-update) — Source: Humacyte
- 2026-05-12 12:00 EST — [Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer](https://biopharmsignal.com/news/HUMA/humacyte-appoints-dr-todd-e-rasmussen-as-chief-surgical-officer) — Source: Humacyte
- 2026-05-08 12:00 EST — [Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026](https://biopharmsignal.com/news/HUMA/humacyte-to-announce-2026-first-quarter-financial-results-and-provide-business-update-on-may-13-2026) — Source: Humacyte
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)